Next Vial Review

Is Next Vial worth it? Our verdict

Next Vial positions itself around one thing: people seeking compounded GLP-1 care with LegitScript certification and a named pharmacy partner. It runs $249.97/month — a premium to the category, so the extras need to justify it. It treats patients in all 50 states, so access isn't a barrier.

How much Next Vial actually costs

• Compounded semaglutide — $249.97/month

For context, the typical ongoing price across the GLP-1 providers we track is around $170/month, so Next Vial's standing rate sits at the premium end.

Medications: what Next Vial prescribes

Next Vial prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products — the standard trade-off across the compounded-GLP-1 market.

Who Next Vial is best for — and who should skip it

A good fit if you…

• live anywhere in the US and want guaranteed access.

Look elsewhere if you…

• want the lowest total cost over 6–12 months — a flat-rate provider will likely beat the ongoing price.
• specifically want an FDA-approved brand-name pen.
• need to bill insurance — like most of this market, it's cash-pay.

Trust, safety, and medical oversight

Next Vial treats patients in all 50 states. We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.

Bottom line

Next Vial costs more than the budget end of the market, so it makes the most sense if its specific extras matter to you. If they don't, you can likely get the same medication for less elsewhere.